Emergence of a Dual Mutant Flu Variant
A rare influenza variant exhibiting resistance to oseltamivir phosphate, commonly known by its brand name Tamiflu, has been detected in at least two individuals in the United States, according to the US Centers for Disease Control and Prevention (CDC). The variant, noted for its dual mutations, raises concerns about the effectiveness of current antiviral treatments.
Characteristics of the Variant
Mutations and Resistance
Influenza viruses are known for their ability to constantly mutate, which can occasionally lead to strains that challenge existing medical treatments. This particular variant carries two significant mutations that appear to reduce the effectiveness of Tamiflu by up to 16-fold, according to laboratory studies cited by the CDC. These mutations have the potential to impact how the virus responds to treatment, although the practical implications in clinical settings remain unclear.
Global Surveillance and Detection
The variant has been detected globally, appearing in 15 countries across five continents, including the two cases reported in the US. Despite its wide geographic distribution, the prevalence of this variant remains low, comprising only about 1% of samples collected between May 2023 and February 2024.
Expert Insights
Spread and Competition
Dr. Andy Pekosz, a virologist at Johns Hopkins Bloomberg School of Public Health, highlighted that the variant has not become dominant in any region where it has been detected. “It’s not like the mutation occurred someplace, and suddenly that particular virus began spreading and out-competing everything in one big wave,” Pekosz noted. Instead, the mutations appear to arise independently in various locations.
Clinical Implications
Dr. William Schaffner, an infectious disease expert at Vanderbilt University, pointed out that the clinical significance of the variant’s resistance is still uncertain. Laboratory findings of resistance do not always translate directly to real-world scenarios. “We don’t know really what the clinical significance of this slight resistance is,” Schaffner said. He suggested that the standard dosage of Tamiflu might still be effective in overcoming the resistance exhibited by the dual mutant variant.
Alternative Treatments and Preventive Measures Influenza Virus
Other Antiviral Options
The CDC’s report provides some reassurance that other antiviral medications remain effective against this dual mutant strain. Baloxavir marboxil, marketed as Xofluza, is a newer antiviral that has shown efficacy against the variant in laboratory tests. This provides an alternative treatment option should Tamiflu prove insufficient.
Influenza Vaccines
The report also indicates that existing flu vaccines are expected to offer protection against infections caused by this variant. Vaccination remains a key strategy in preventing the spread of influenza, including strains with mutations.
Ongoing Monitoring and Public Health Impact
Continuous Surveillance
The CDC emphasized the importance of ongoing global surveillance in monitoring the antiviral susceptibility of circulating influenza viruses. “There’s active global surveillance going on looking for these mutations,” Pekosz stated. This surveillance is crucial in assessing the potential public health threat posed by new influenza variants.
Current Risk Assessment
Despite the presence of the dual mutant variant, experts currently consider the overall threat to be low. The rarity of the variant and its inability to dominate other strains suggest it is not an immediate concern for widespread public health. “They appear in a lot of places, but they’re never really the dominant virus in any place they appear,” Pekosz reiterated.
The discovery of a rare, drug-resistant influenza variant in the US and globally underscores the need for vigilant monitoring and research. While the dual mutations present potential challenges, existing antiviral treatments and vaccines are likely to remain effective. Continuous global surveillance will be essential in identifying and responding to any emerging threats posed by such influenza variants, ensuring preparedness and protection of public health.
Join TISHHA.
